Condition: Schizophrenia · Sponsor: Neurocrine Biosciences
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
This description comes directly from the study's public registry record.
Neurocrine Medical Information Call Center · 877-641-3461 · medinfo@neurocrine.com
Always discuss trial participation with your own doctor first.
| Neurocrine Clinical Site | Culver City, California, United States | Recruiting |
| Neurocrine Clinical Site | Garden Grove, California, United States | Recruiting |
| Neurocrine Clinical Site | Riverside, California, United States | Recruiting |
| Neurocrine Clinical Site | Atlanta, Georgia, United States | Recruiting |
| Neurocrine Clinical Site | North Canton, Ohio, United States | Recruiting |
| Neurocrine Clinical Site | Sliven, Bulgaria | Recruiting |
| Neurocrine Clinical Site | Veliko Tarnovo, Bulgaria | Withdrawn |
| Neurocrine Clinical Site | Vratsa, Bulgaria | Recruiting |
| Neurocrine Clinical Site | Győr, Hungary | Recruiting |
| Neurocrine Clinical Site | Brasov, Romania | Recruiting |
| Neurocrine Clinical Site | Brasov, Romania | Recruiting |
| Neurocrine Clinical Site | Bucharest, Romania | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07105098